Deep Mind's AI for Drug Discovery
GPTKB entity
Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:technology
|
| gptkbp:addressed |
antimicrobial resistance
global health challenges |
| gptkbp:aims_to |
accelerate drug development
|
| gptkbp:analyzes |
protein structures
|
| gptkbp:collaborated_with |
academic institutions
|
| gptkbp:collaborates_with |
biopharmaceutical companies
|
| gptkbp:contributed_to |
personalized medicine
|
| gptkbp:developed_by |
gptkb:philosopher
|
| gptkbp:developer |
new therapeutic agents
|
| gptkbp:engages_in |
regulatory bodies
|
| gptkbp:explores |
novel drug targets
|
| gptkbp:facilitates |
collaborative research
cross-disciplinary collaboration |
| gptkbp:focuses_on |
drug discovery
|
| gptkbp:fosters |
innovation in pharmaceuticals
|
| gptkbp:future_plans |
transform drug development
|
| gptkbp:has_achievements |
molecular interactions
|
| gptkbp:has_programs |
neurology
oncology infectious diseases |
| gptkbp:has_transformation |
healthcare delivery
traditional drug discovery methods |
| https://www.w3.org/2000/01/rdf-schema#label |
Deep Mind's AI for Drug Discovery
|
| gptkbp:improves |
success rates in clinical trials
|
| gptkbp:increased |
efficiency in research
|
| gptkbp:integrates_with |
genomic data
|
| gptkbp:is_analyzed_in |
large datasets
|
| gptkbp:is_enhanced_by |
data analysis capabilities
patient outcomes collaboration between disciplines research productivity drug design processes |
| gptkbp:is_evaluated_by |
gptkb:Research_Institute
|
| gptkbp:is_influenced_by |
biological data
|
| gptkbp:is_part_of |
gptkb:hospital
healthcare innovation |
| gptkbp:is_recognized_by |
gptkb:Research_Institute
|
| gptkbp:is_supported_by |
computational power
|
| gptkbp:notable_recipients |
public health initiatives
|
| gptkbp:origin |
biomedical research
|
| gptkbp:participated_in |
clinical trials
|
| gptkbp:promotes |
data sharing
|
| gptkbp:provides |
insights into disease mechanisms
|
| gptkbp:receives_funding_from |
AI technologies
|
| gptkbp:reduces |
time to market for drugs
costs in drug development |
| gptkbp:supports |
clinical decision making
|
| gptkbp:uses |
gptkb:software_framework
AI algorithms |
| gptkbp:utilizes |
gptkb:microprocessor
predictive modeling data-driven approaches |
| gptkbp:bfsParent |
gptkb:philosopher
|
| gptkbp:bfsLayer |
3
|